PREDICT
Computational prediction of drug cardiac toxicity
| Coordinatore | THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
Organization address
address: University Offices, Wellington Square contact info |
| Nazionalità Coordinatore | United Kingdom [UK] |
| Totale costo | 5˙545˙692 € |
| EC contributo | 4˙100˙000 € |
| Programma | FP7-ICT
Specific Programme "Cooperation": Information and communication technologies |
| Funding Scheme | CP |
| Anno di inizio | 2008 |
| Periodo (anno-mese-giorno) | 2008-06-01 - 2011-05-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
Organization address
address: University Offices, Wellington Square contact info |
UK (OXFORD) | coordinator | 0.00 |
| 2 |
AUREUS PHARMA SA
Organization address
address: QUAI DE JEMMAPES 174 contact info |
FR (PARIS 10) | participant | 0.00 |
| 3 |
CENTRO DI RICERCA, SVILUPPO E STUDI SUPERIORI IN SARDEGNA
Organization address
address: Via Palabanda 9 contact info |
IT (CAGLIARI) | participant | 0.00 |
| 4 |
F. HOFFMANN-LA ROCHE AG
Organization address
address: GRENZACHERSTRASSE 124 contact info |
CH (BASEL) | participant | 0.00 |
| 5 |
FUJITSU LABORATORIES OF EUROPE LIMITED
Organization address
address: HAYES PARK CENTRAL, HAYES END ROAD contact info |
UK (HAYES, MIDDLESEX) | participant | 0.00 |
| 6 |
GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LTD.
Organization address
address: Great West Road 980 contact info |
UK (BRENTFORD) | participant | 0.00 |
| 7 |
NOVARTIS PHARMA AG
Organization address
address: LICHTSTRASSE 35 contact info |
CH (BASEL) | participant | 0.00 |
| 8 |
SZEGEDI TUDOMANYEGYETEM
Organization address
address: DUGONICS TER 13 contact info |
HU (SZEGED) | participant | 0.00 |
| 9 |
UNIVERSIDAD POLITECNICA DE VALENCIA
Organization address
address: Camino de Vera s/n contact info |
ES (VALENCIA) | participant | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
Many drugs fail to reach the market because of side effects on the heart. The principal objective of this proposal is to create an advanced computational technology for in silico assessment of the efficacy and safety of specific drugs [ICT-2007.5.3(c) (3)], i.e. an open environment comprising validated computational models, tools and numerical methods that will enable simulations of drug actions on the electrophysiology of the human heart.
Such simulations will involve modelling of drug interactions at the molecular and cellular level, will extend current technology to enable prediction of the effects of those interactions on the dynamics of the whole heart, and will lead to an understanding of how genetic factors can be used to assess patient-specific risk profiles. This requires a multi-level systems approach, based on multi-scale, multi-physics methods, including computations on adaptive spatial grids and multi-grid time integration. Computations on realistic models at appropriate spatial and temporal scales are currently not feasible, so we will investigate new algorithms and their implementation on high-performance platforms, including a new generation of petaflop computers, to achieve 'faster than real-time' simulation.
These tools form part of the infrastructure required to simulate the physiology of major organ systems, thereby contributing to the goal of creating the Virtual Physiological Human (VPH) [ICT-2007.5.3]. The balanced team in this project, including founders of the Human Physiome Project, has decades of experience in the experimental study and modelling of the electrophysiology and mechanics of the heart, while pharmaceutical industry partners bring deep understanding of the mechanisms of drug actions. The results will demonstrate the value of the VPH initiative to fundamental scientific understanding of the heart, with major economic and clinical impacts through accelerated drug development, approval and use.